Photo of Stephen T. Sonis,  DMD, DMSc

Stephen T. Sonis, DMD, DMSc

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (857) 228-1102
Fax: (852) 228-1101


ssonis@partners.org

Stephen T. Sonis, DMD, DMSc

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Harvard-Forsyth Oral Biology, Harvard School Of Dental Medicine
  • Chief, Division of Oral Medicine, Surgery, Dana-Farber Cancer Institute
  • Senior Physician, Oral and Maxillofacial Surgery and Dentistry, Brigham And Women's Hospital

Research Abstract

Toxicities have long been associated with cancer treatment regimens and may result in tissue damage and behavioral impairment. Studies by our group focus on understanding the fundamental biological processes that, when triggered by cancer drugs or radiation, lead to these events, identifying the genetic factors that predispose patients to toxicities, and developing and testing effective toxicity interventions. Using animal models which closely mimic human responses to cancer drugs or radiation therapy, we have identified the biological pathways that are associated with injuries of the GI tract, skin, and lung, cancer regimen-related cognitive dysfunction and cancer-related fatigue. Using novel analytics, we have been able to identify specific clustered DNA fragments that, when obtained from the saliva of patients before treatment, can effectively predict toxicity risk. And with industry partners, have applied modeling to assist in the development of effective preventive treatments for regimen-related toxicities. As part of an international collaboration, we participate in ongoing assessments of the health and economic burdens of the toxicities of cancer therapy and supportive cancer care.

Publications

Powered by Harvard Catalyst
  • Villa A, Stock S, Aboalela A, Lerman MA, Woo SB, Sonis ST, Treister NS. Oral Medicine referrals at a hospital-based practice in the United States. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 119:423-9. PubMed
  • Villa A, Aboalela A, Luskin KA, Cutler CS, Sonis ST, Woo SB, Peterson DE, Treister NS. Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21:503-8. PubMed
  • Wardill HR, Van Sebille YZ, Mander KA, Gibson RJ, Logan RM, Bowen JM, Sonis ST. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treat Rev 2015; 41:122-8. PubMed
  • Mawardi HH, Elbadawi LS, Sonis ST. Current understanding of the relationship between periodontal and systemic diseases. Saudi Med J 2015; 36:150-8. PubMed
  • Sonis ST. Genomics, personalized medicine, and supportive cancer care. Am Soc Clin Oncol Educ Book 2015; 35:9-16. PubMed
  • Keefe DM, Elting LS, Nguyen HT, Grunberg SM, Aprile G, Bonaventura A, Selva-Nayagam S, Barsevick A, Koczwara B, Sonis ST. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother Pharmacol 2014; 74:675-80. PubMed
  • Lalla RV, Choquette LE, Curley KF, Dowsett RJ, Feinn RS, Hegde UP, Pilbeam CC, Salner AL, Sonis ST, Peterson DE. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol 2014. PubMed
  • Allison RR, Ambrad AA, Arshoun Y, Carmel RJ, Ciuba DF, Feldman E, Finkelstein SE, Gandhavadi R, Heron DE, Lane SC, Longo JM, Meakin C, Papadopoulos D, Pruitt DE, Steinbrenner LM, Taylor MA, Wisbeck WM, Yuh GE, Nowotnik DP, Sonis ST. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck Cancer 2014; 120:1433-40. PubMed
  • Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis. Radiat Res 2014. PubMed
  • Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, . MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014. PubMed
  • Guze K, Pawluk HC, Short M, Zeng H, Lorch J, Norris C, Sonis S. Pilot study: Raman spectroscopy in differentiating premalignant and malignant oral lesions from normal mucosa and benign lesions in humans. Head Neck 2014. PubMed
  • Mancini ML, Sonis ST. Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Front Pharmacol 2014; 5:51. PubMed
  • Russi EG, Raber-Durlacher JE, Sonis ST. Local and Systemic Pathogenesis and Consequences of Regimen-Induced Inflammatory Responses in Patients with Head and Neck Cancer Receiving Chemoradiation. Mediators Inflamm. 2014; 2014:518261. PubMed
  • Limaye SA, Haddad RI, Cilli F, Sonis ST, Colevas AD, Brennan MT, Hu KS, Murphy BA. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 2013; 119:4268-76. PubMed
  • Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV, . Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013; 21:3233-41. PubMed
  • Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. 2013; 31:753-66. PubMed
  • Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol 2013. PubMed
  • Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, Logan RM, Nair RG, Stringer AM, Yazbeck R, Elad S, Lalla RV, . Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013. PubMed
  • Sonis ST. Oral mucositis in head and neck cancer. Am Soc Clin Oncol Educ Book 2013. PubMed
  • Zombeck JA, Fey EG, Lyng GD, Sonis ST. A clinically translatable mouse model for chemotherapy-related fatigue. Comp Med 2013; 63:491-7. PubMed
  • Sonis ST. Regimen-related gastrointestinal toxicities in cancer patients. Curr Opin Support Palliat Care 2010; 4:26-30. PubMed
  • Murray LA, Kramer MS, Hesson DP, Watkins BA, Fey EG, Argentieri RL, Shaheen F, Knight DA, Sonis ST. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. 2010; 3:11. PubMed
  • Sonis ST. Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid 2010; 4:199-205. PubMed
  • Sonis ST. Mucositis: The impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 2009; 45:1015-20. PubMed
  • Rankin KV, Epstein J, Hubber MA, Peterson DE, Plemons JM, Redding SS, Sanfillippo NJ, Schubert MM, Sonis ST. Oral health in cancer therapy. Todays FDA 2009; 21:37, 39-45. PubMed
  • Rankin KV, Epstein J, Huber MA, Peterson DE, Plemons JM, Redding SS, Sanfillippo NJ, Schubert MM, Sonis ST. Oral health in cancer therapy. 2009; 126:389-97, 406-19, 422-37. PubMed
  • Sonis ST,Watkins BA,Lyng GD,Lerman MA,Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2008; 45:164-72. PubMed
  • Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2008; 63:239-51. PubMed
  • Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41. PubMed
  • Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, Larochelle WJ. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol 2008; 84:401-12. PubMed
  • Aprile G, Ramoni M, Keefe D, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 2007; 112:284-92. PubMed
  • Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am 2007; 52:61-77, viii. PubMed
  • Tanner AC, Kent R Jr, Kanasi E, Lu SC, Paster BJ, Sonis ST, Murray LA, Van Dyke TE. Clinical characteristics and microbiota of progressing slight chronic periodontitis in adults. J Clin Periodontol 2007; 34:917-30. PubMed
  • Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5:3-11. PubMed
  • Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, Keefe DM. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33:448-60. PubMed
  • Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 2006; 15:491-6. PubMed
  • Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol 2007; 5:231-5. PubMed
  • Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2006; 18:817-26. PubMed
  • Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2006; 43:395-401. PubMed
  • Treister N, Sonis S. Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 2007; 15:123-9. PubMed
  • Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2006; 43:289-300. PubMed
  • Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE,. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109:820-31. PubMed
  • Sonis ST. Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation? Nat Clin Pract Oncol 2006; 3:244-5. PubMed
  • Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2005; 106:329-36. PubMed
  • Sonis S. New trends in the management of oral mucositis. J Natl Compr Canc Netw 2005; 3 Suppl 1:S54-6. PubMed
  • Hwang D, Popat R, Bragdon C, O'Donnell KE, Sonis ST. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:321-9. PubMed
  • Stokman MA, Sonis ST, Dijkstra PU, Burgerhof JG, Spijkervet FK. Assessment of oral mucositis in clinical trials: impact of training on evaluators in a multi-centre trial. Eur J Cancer 2005; 41:1735-8. PubMed
  • Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11:383-8. PubMed
  • Sonis ST. Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers? Nat Clin Pract Oncol 2005; 2:134-5. PubMed
  • Kang SJ, Popat R, Bragdon C, Odonnell K, Phelan S, Yuan J, Sonis ST. Caspase-11 is not necessary for chemotherapy-induced intestinal mucositis. DNA Cell Biol 2004; 23:490-5. PubMed
  • Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, ,. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995-2025. PubMed
  • Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST, ,. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100:2026-46. PubMed
  • Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:328-36. PubMed
  • Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277-84. PubMed
  • Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 2003; 40:170-6. PubMed
  • Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100:3479-82. PubMed
  • Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, Ferrara JL. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:373-7. PubMed
  • Sonis S, Antin J, Tedaldi M, Alterovitz G. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients Oral Dis 2013; 19:721-7.
  • Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett WH, Mulagha MT, Peterson DE, Rose AH, Schubert MM, Spijkervet FK, Wittes JP. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999; 85:2103-13. PubMed
  • Loury D, Embree JR, Steinberg DA, Sonis ST, Fiddes JC. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87:544-51. PubMed
Hide